We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+29.4%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.45B
AUM Growth
+$253M
Cap. Flow
-$260M
Cap. Flow %
-7.53%
Top 10 Hldgs %
43.88%
Holding
127
New
16
Increased
25
Reduced
24
Closed
11

Top Buys

Rank Stock Value
1
RLMD icon
Relmada Therapeutics
RLMD
+$62.7M
2
BLU
BELLUS Health Inc.
BLU
+$50.1M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$48.2M
4
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$42.4M
5
EW icon
Edwards Lifesciences
EW
+$31.8M

Top Sells

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$38.2M
2
LLY icon
Eli Lilly
LLY
+$32.4M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$30.2M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$25.2M
5
CHRS icon
Coherus Oncology
CHRS
+$20M

Sector Composition

Rank Sector Weight
1 Healthcare 97.49%
2 Financials 0.19%
3 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOLD
1
DELISTED
Amicus Therapeutics
FOLD
$286M 8.29%
27,372,917
+477,385
+2% +$5.32M
MRTX
2
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$194M 5.64%
2,784,796
-82,067
-3% -$6.07M
CERE
3
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$184M 5.34%
6,511,727
+1,425,000
+28% +$42.4M
GBT
4
DELISTED
Global Blood Therapeutics, Inc.
GBT
$158M 4.59%
2,322,247
-692,807
-23% -$38.2M
AMLX icon
5
Amylyx Pharmaceuticals
AMLX
$2.16B
$154M 4.47%
5,472,033
+1,931,625
+55% +$48.2M
LIAN
6
DELISTED
LianBio American Depositary Shares
LIAN
$115M 3.34%
57,558,451
+998,240
+2% +$2.39M
CINC
7
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$109M 3.15%
3,306,649
+987,532
+43% +$27.9M
BLU
8
DELISTED
BELLUS Health Inc.
BLU
$108M 3.14%
10,247,073
+4,712,904
+85% +$50.1M
CRNX icon
9
Crinetics Pharmaceuticals
CRNX
$8.88B
$105M 3.03%
5,321,032
– –
SWTX
10
DELISTED
SpringWorks Therapeutics
SWTX
$99M 2.87%
3,470,563
-396,883
-10% -$11.4M
IOVA icon
11
Iovance Biotherapeutics
IOVA
$2.04B
$98.2M 2.85%
10,248,624
-1,577,675
-13% -$18.2M
RLMD icon
12
Relmada Therapeutics
RLMD
$536M
$88.2M 2.56%
2,383,478
+2,262,128
+1,864% +$62.7M
RXDX
13
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$86.7M 2.52%
1,468,512
-213,730
-13% -$9.78M
XENE icon
14
Xenon Pharmaceuticals
XENE
$6.21B
$76.6M 2.22%
2,122,535
– –
ALDX icon
15
Aldeyra Therapeutics
ALDX
$95.9M
$60.6M 1.76%
11,350,085
+1,446,206
+15% +$8.68M
MGTX icon
16
MeiraGTx Holdings
MGTX
$1.08B
$58.6M 1.7%
6,963,277
– –
INBX
17
DELISTED
Inhibrx, Inc. Common Stock
INBX
$51.8M 1.5%
2,887,860
+973,268
+51% +$17.5M
VRNA
18
DELISTED
Verona Pharma
VRNA
$51.6M 1.5%
5,047,264
+2,132,118
+73% +$18M
COGT icon
19
Cogent Biosciences
COGT
$6.82B
$47.9M 1.39%
3,207,441
+118,469
+4% +$1.62M
ACLX
20
DELISTED
Arcellx
ACLX
$46.3M 1.34%
2,465,405
+1,323,415
+116% +$25.3M
LYRA
21
DELISTED
LYRA THERAPEUTICS INC
LYRA
$45.8M 1.33%
182,935
– –
ALBO
22
DELISTED
Albireo Pharma Inc
ALBO
$45.7M 1.33%
2,360,139
– –
VERU icon
23
Veru
VERU
$35.5M
$44.8M 1.3%
389,300
+39,300
+11% +$5.67M
RLAY icon
24
Relay Therapeutics
RLAY
$3.96B
$43.5M 1.26%
1,943,097
– –
SGEN
25
DELISTED
Seagen Inc. Common Stock
SGEN
$43.3M 1.26%
316,544
+92,544
+41% +$15.1M
1
2 3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q3 2022 Portfolio in Review

As of Q3 2022, Perceptive Advisors held 127 positions worth $3.45B, up 7.9% from $3.19B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Perceptive Advisors withdrew a net $260M in Q3 2022, closing 11 positions and reducing 24 holdings. Its most notable exit was Eli Lilly, an estimated $32.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 83% a quarter earlier, followed by Financials and Consumer Discretionary.

Against the trend, Perceptive Advisors opened a new position in Edwards Lifesciences worth $27.3M.

  • Perceptive Advisors's largest Q3 2022 buy was Edwards Lifesciences: 330,000 shares worth $27.3M.
  • Perceptive Advisors added most to Relmada Therapeutics in Q3 2022, an estimated $62.7M increase.
  • Perceptive Advisors's biggest Q3 2022 reduction was Global Blood Therapeutics, Inc., cutting an estimated $38.2M.
  • Perceptive Advisors fully exited Eli Lilly in Q3 2022, selling an estimated $32.4M.
  • Perceptive Advisors's ten largest holdings make up 44% of its $3.45B portfolio in Q3 2022.
  • Perceptive Advisors opened 16 new positions and closed 11 in Q3 2022.
  • Perceptive Advisors's portfolio value rose 7.9% quarter-over-quarter to $3.45B.

Based on Perceptive Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.